AZN vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 17, 2026
AZN
56.8
AI Score
VS
AZN Wins
MRNA
42.8
AI Score
Investment Advisor Scores
MRNA
43score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | AZN | MRNA | Winner |
|---|
Relative Price Performance (Last 90 Days)
AZN 1M: -2.9%
· 3M: -17.5%
MRNA 1M: +26.0%
· 3M: +132.3%
Current Technical Phase
AZN
MarkdownSell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 38
MRNA
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (47.6% over 20 days), RSI 66
Fundamentals Snapshot
| Metric | AZN | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.6 | -39.7 |
| Trailing P/E | 23.6 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.8% | -0.7% |
| Operating Margin | 0.2% | -5.6% |
| EPS | 6.68 | -7.82 |
| Dividend Yield | 0.02% | — |
Frequently Asked Questions
Based on our detailed analysis, AZN is currently the stronger investment candidate based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.